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Abstract
Introduction: Galectin-3 (Gal-3) is an independent predictor of poor outcomes and mortality in patients with heart failure (HF). Thus, it has been 
proposed as a reliable prognostic biomarker for HF. The definition of reference intervals is mandatory for interpreting the findings of experimental 
studies and encouraging the routine use of biomarkers in clinical practice. To date, no study assessed the reference intervals of Gal-3 and identified 
the biological variables that affect its concentration in a well-defined healthy population. The aim of this study was to determine the upper referen-
ce limit (URL) of Gal-3 in a highly reliable population of healthy subjects. 
Materials and methods: We recruited 714 blood donors. After measuring surrogate biomarkers to identify underlying diseases, 8 subjects were 
excluded. A final population of 706 individuals (385 men (54.5%); median age 39 (18-65) years) was included. The URL was calculated using the non-
parametric percentile approach. 
Results: The 97.5th percentile URL of plasma Gal-3 in our study population (90% CI) was 26.1 (23.3–31.5) ng/mL. After stratifying subjects according 
to age, the URL of Gal-3 was found to be considerably higher in older (> 45 years) than in younger subjects (31.5 (26.2–51.4) vs 21.8 (21–26.1) ng/mL, 
respectively). No sex-related differences were found in Gal-3 plasma concentration. 
Conclusions: We established the URL of Gal-3 in a highly selected healthy population. Our findings indicate that age is an important determinant of 
Gal-3 plasma concentration, so that multiple diagnostic cut-offs should be preferably used according to the different age classes.  
Key words: galectin-3; blood donors; heart failure; reference values; upper reference limit (URL)
Received: April 28, 2017 Accepted: August 31, 2017
Establishing the upper reference limit of Galectin-3 in healthy blood donors
Luisa Agnello1, Chiara Bellia1, Bruna Lo Sasso1, Alessia Pivetti1, Maddalena Muratore2, Concetta Scazzone1, Giulia Bivona1, Giuseppe 
Lippi3†, Marcello Ciaccio*1,4†
1Section of Clinical Biochemistry and Clinical Molecular Medicine, Department of Biopathology and Medical Biotechnologies, Uni-
versity of Palermo, Italy
2Unit of Trasfusional Medicine, Villa Sofia-Cervello Hospital, Palermo, Italy 
3Section of Clinical Biochemistry, University of Verona, Italy
4UOC of Laboratory Medicine, AOUP “P. Giaccone”, Palermo, Italy




Galectin-3 (Gal-3) is a highly versatile lectin in-
volved in several physiological and pathological 
processes including inflammation and fibrosis, 
which are pivotal events in development and pro-
gression of adverse cardiac remodelling and heart 
failure (HF) (1,2). Gal-3 is receiving growing atten-
tion due to its potential role in HF, from risk evalua-
tion to diagnosis, prognosis and therapy. Ho et al. 
showed that increased Gal-3 concentrations were 
associated with an enhanced risk of new-onset HF 
in apparently healthy subjects recruited from the 
Framingham Heart Study (3). Many clinical studies 
also investigated the clinical value of Gal-3 for pre-
dicting HF in cardiac disorders such as atrial fibril-
lation and acute coronary syndrome, achieving 
controversial results (4-6). Strong evidence sup-
ports the role of Gal-3 as a prognostic biomarker 
in both acute and chronic HF (7-9). Notably, Gal-3 
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has also been recently included in the American 
College of Cardiology Foundation (ACCF) and the 
American Heart Association (AHA) Guidelines for 
Management of Heart Failure, as an emerging bio-
marker for additive risk stratification in HF patients 
(10). However, they do not deal with the problem 
of reference intervals. 
Since Gal-3 holds great promises in diagnosis, prog-
nostication and therapeutic management of HF, the 
availability of an accurate reference range and the 
knowledge of the variables that could influence its 
concentrations is essential to promote clinical re-
search and for its diagnostic application. To date, 
only few studies have been published on the refer-
ence intervals of plasma Gal-3, and most of these 
were carried out on presumably healthy popula-
tions, not carefully characterized and without repre-
sentative number of individuals (11-13). Thus, there 
is no consensus on the cut-off values for Gal-3.
Therefore, the aim of this study was to define the 
upper reference limit (URL) of plasma Gal-3 in a 
healthy population carefully selected by a screen-
ing method based on surrogate blood biomarkers. 
We chose to refer only to URL because lower refer-
ence limit has no clinical significance.
Materials and methods
Study design and subjects 
This observational study originally included 714 
consecutive blood donors recruited from the Unit 
of Transfusion Medicine of Villa Sofia-Cervello Hos-
pital in Palermo, from April to July 2016. Health sta-
tus of blood donors was assessed in two steps. 
First, the donors filled a questionnaire about their 
past and present health status and lifestyle. Then, 
they underwent to a physical examination includ-
ing the collection of anthropometric parameters, 
arterial pressure, personal and family medical his-
tory. During physical examination a blood sample 
was collected for the determination of routine clin-
ical chemistry and infectious disease testing. Ad-
mission to donation was determined according to 
local law. Particularly, in Italy donation criteria are 
published on Gazzetta Ufficiale Repubblica Itali-
ana, 28 December 2015, ordinary supplement nr. 69. 
Exclusion criteria for donation were cancer, auto-
immune or cardiovascular diseases (e.g., coronary 
artery disease, angina, cardiac arrhythmias, history 
of cerebrovascular diseases, arterial thrombosis, 
recurrent deep vein thrombosis, hypertension 
with organ damage), organic diseases of the cen-
tral nervous system (CNS), transplant recipients, di-
agnosis of haemostatic disorders, epilepsy, ana-
phylaxis, drug use, chronic alcoholism, infectious 
diseases and any chronic hepatic, gastrointestinal, 
urogenital, haematologic, immunologic, renal, 
metabolic and respiratory disorder. Diabetics with 
good glycemic control and not needing insulin 
treatment were admitted for donation. Glycemic 
control was evaluated based on self-reported 
HbA1c < 53 mmol/L, preprandial plasma glucose 
between 4.4 and 7.2 mmol/L, and postprandial 
plasma glucose < 10 mmol/L according to Ameri-
can Diabetes Association Diabetes (ADA) guide-
lines (14). Selected biomarkers were used to iden-
tify clinically asymptomatic diseases, and further 
refine the study population. In particular, we used 
B-type natriuretic peptide (BNP) and high sensitiv-
ity troponin I (hsTnI) to assess myocardial dysfunc-
tion, and creatinine for estimated Glomerular Fil-
tration Rate (eGFR) calculation to assess kidney dis-
ease. Plasma concentration of BNP > 104 pg/mL in 
men and > 150 pg/mL in women, plasma concen-
tration of hsTnI > 34.2 ng/L in men and > 15.6 ng/L 
in women, as for manufacturer cut-offs; and an 
eGFR < 60 mL/min/1.73m2 were applied as exclu-
sion criteria, according to The Kidney Disease: Im-
proving Global Outcomes (KDIGO) guidelines (15). 
The study protocol was approved by the local eth-
ics committee and was performed in accordance 
with the Declaration of Helsinki. 
Overall 8 subjects from the original population of 
714 blood donors ought to be excluded due to 
values of hsTnI (N = 7) or BNP (N = 1) above the re-
spective URL. None of the subjects had an eGFR ≤ 
60 mL/min/1.73m2. Therefore, the final study pop-
ulation consisted of 706 subjects, aged from 18 to 
65 years, with a median age of 39 years (interquar-
tile range, IQR: 18 – 65 years) and with a slightly 
higher rate of men (N = 385, i.e. 54.5%). All study 
participants gave an informed consent. 
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Methods
Blood samples were collected in tube containing 
K2EDTA (Greiner Bio-One GmbH, 454086, Kremsm-
uenster, Austria) in the morning after night fasting 
(8 hours). Upon arrival at the Transfusion Medicine 
Unit, K2EDTA plasma was separated by centrifuga-
tion for 10 minutes at 3000 rpm at room tempera-
ture and subsequently frozen in aliquots at - 80°C 
until testing. In particular, we analyzed plasma 
samples within 3 months of the collection because 
BNP has a stability ≤ 3 months at - 20°C or colder, 
as stated by manufacturer; the other analytes are 
stable within this interval. The concentration of 
hsTnI was measured using the Architect STAT High 
Sensitive Troponin-I assay, which has a limit of de-
tection (LoD) comprised between 1.1-1.9 ng/L and 
an imprecision (CV %) lower than 10% at the 99th 
percentile of healthy subjects distribution, as de-
clared by the manufacturer. The concentration of 
BNP was measured by the Architect BNP assay, 
which displays a LoD < 10 pg/mL and an impreci-
sion (CV %) < 12%, as declared by manufacturer. 
Gal-3 was measured by the Architect STAT Galec-
tin-3 immunoassay. This assay is characterized by a 
LoD of 1 ng/mL and a total CV ≤ 6.2% for Gal-3 val-
ues between 8.5 and 94.4 ng/mL, as declared by 
manufacturer. Measurements of hsTnI, BNP and 
Gal-3 were performed on Architect i1000 instru-
ment (Abbott Laboratories, Wiesbaden, Germany). 
A calibration was performed before using a new 
lot number for each of these assays. A single sam-
ple of low, medium and high concentration con-
trol was tested to evaluate the assay calibration 
once every 24 hours each day of use. Serum creati-
nine was measured using the Architect C8000 in-
strument and reagents (Abbott Laboratories, 
Wiesbaden, Germany) based on a kinetic alkaline 
picrate method, traceable to isotope dilution mass 
spectrometry (IDMS) method and NIST SRM 967 
standard. Estimated glomerular filtration rate 
(eGFR) was calculated using the Chronic Kidney 
Disease - Epidemiology Collaboration (CKD-EPI) 
equation (16). We took into account situations that 
could limit the use of GFR estimating equations.
The methods were sensitive to haemolysis, lipemic 
material, fibrin and other particular material in-
cluding cryoprecipitate. In this cases the manufac-
turer suggests performing a particular procedure 
before testing sample to ensure consistency in re-
sults. However, we did not have unacceptable 
samples.
Statistical analysis
Data were statistically analyzed with SPSS Software 
15.0 (SPSS Inc., Chicago, IL, USA). Non-normally dis-
tributed continuous variables were reported as 
median and interquartile range (IQR). Categorical 
variables were shown as percentage. Normality of 
distribution was assessed using the Kolmogorov-
Smirnov test. Differences between normally dis-
tributed variables were evaluated using ANOVA. 
Differences in Gal-3 concentrations according to 
age, sex and eGFR groups were evaluated by the 
non-parametric Kruskal - Wallis test because Gal-3 
was non-normally distributed. The correlation be-
tween Gal-3 and age was evaluated by the Spear-
man rank correlation test. The URL was finally cal-
culated with the non-parametric percentile meth-
od, according to the Clinical and Laboratory Stand-
ard Institute – CSLI C28-A3 document, considering 
values in the 97.5% of the distribution (17). This 
method is recommended for asymmetric distribu-
tion of non-normally distributed variables, such as 
for Galectin-3 in our study. The statistical signifi-
cance of P < 0.05 was accepted for all tests.
Results
None of the subjects included in this study dis-
played a Gal-3 plasma concentration lower than the 
LoD of the assay. A non-Gaussian (right-skewed) dis-
tribution of Gal-3 values was observed (Figure 1). 
Notably, the plasma concentration of Gal-3 was 
not found to be statistically different between 
men and women (14.4 (12.4–16.5) ng/mL vs 14.1 
(11.5–16.9) ng/mL; P = 0.19), whereas plasma Gal-3 
values were found to be significantly correlated 
with age (r = 0.27; P < 0.01) (Figure 2). 
In this study population, the vast majority of sub-
jects had eGFR > 90 mL/min/1.73m2, with only 117 
subjects (16.6%) having eGFR between 60 and 89 
mL/min/1.73m2. After stratifying the population 
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according to eGFR values, we found that subjects 
with modestly decreased renal function (eGFR 60-
89 mL/min/1.73m2) had slightly higher Gal-3 plas-
ma values than those with normal eGFR (eGFR > 
90 mL/min/1.73m2) (15.2 (12.5–18) ng/mL vs 14.1 
(11.8–16.4) ng/mL; P = 0.004).
The URL of Gal-3 is shown in Table 1. When sub-
jects were stratified according to their age, the 
URL of Gal-3 were considerably higher in older (i.e., 
> 45 years) compared to younger subjects (P < 
0.001). The choice of 45 years as cut-off age was ar-
bitrary. Given the correlation between Gal-3 and 
age and the higher prevalence of cardiovascular 
disease in aged populations, we decided to identi-
fy an age specific reference limit. Therefore, the 
choice of this cut-off allowed us to analyze an old-
er population without limiting the statistical signif-
icance of the analysis due to a very small sample.
Discussion 
In this study we defined the URL of Gal-3 plasma 
concentrations in a reference population repre-
senting “truly” healthy individuals, including blood 
donors strictly selected by using surrogate bio-
markers. Moreover, the study population is ethni-
cally homogeneous, only consisting of Caucasian 
subjects born in our country (Italy), and holding an 
almost identical number of men and women. The 
most relevant finding of our study is the age-relat-
ed difference in Gal-3 plasma concentration. Addi-
tionally, we found an association between Gal-3 
plasma levels and eGFR.  Finally, we did not find 
sex-related differences in Gal-3 concentrations. 
Galectin-3 is a biomarker of inflammation and fi-
brosis, displaying a well-established prognostic 
value in HF patients (18). The clinical use of this bi-
Subjects N
Galectin-3 concentrations (ng/mL)
Median (IQR) 97.5th percentile (90% CI)
All 706 14.3 (11.9 – 16.7) 26.1 (23.3 – 31.5) 
Age ≤ 45 years 470 13.6 (11.5 – 15.9) 21.8 (21 – 26.1)
Age > 45 years 236 15.5 (12.9 – 18.3)* 31.5 (26.2 – 51.4)*
IQR - interquartile range. CI -confidence interval. *P < 0.001 when compared with subjects aged ≤ 45 years.
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Table 1. Upper reference limit of plasma galectin-3 concentration
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omarker has been proposed along with natriuretic 
peptides to identify patients at higher risk of re-
admission or death of HF (10). Nevertheless, before 
the measurement of Gal-3 can be thoughtfully in-
troduced in clinical practice, it is imperative to 
identify its reference values and the potential in-
fluence of biological variables on its circulating 
levels in the general population of healthy sub-
jects. 
The URL of plasma Gal-3, namely the 97.5th per-
centile of the distribution, identified in our study 
was 26.1 ng/mL. In a previous study, Gaze et al. es-
timated a quite similar URL value (28.4 ng/mL) in 
627 apparently healthy individuals (11). Unlike this 
data, Krintus et al. and La’ulu et al. calculated a 
much lower URL in their study populations (18.1 
ng/mL and 18.7 ng/mL, respectively) (12,19). Nota-
bly, these two studies were performed using the 
same Galectin-3 assay (Abbott) used in our investi-
gation. Similarly to Mueller et al. we found an in-
verse association between Gal-3 plasma values 
and eGFR (20). The relation between Gal-3 and re-
nal function has been previously documented. 
Gal-3 has been linked to development of renal fi-
brosis in animal models, and was found to be in-
versely correlated with eGFR in humans (21,22). In 
our study, subjects with a modestly decreased re-
nal function (eGFR 60-89 mL/min/1.73m2) were 
not excluded from the reference population, since 
this aspect had an insignificant impact on Gal-3 
plasma concentrations. 
Interestingly, we failed to find sex-related differ-
ences in plasma Gal-3 concentrations in our highly 
selected study population. This finding is in ac-
cordance with data published by Krintus et al., but 
it is in disagreement with those of La’ulu et al. and 
Gaze et al., who found higher Gal-3 concentrations 
in men, as well as with those of Mueller et al., who 
found higher Gal-3 concentrations in women than 
in men (11,12,19,20). Finally, a strong correlation be-
tween Gal-3 plasma concentration and age was 
found in our study, with increased Gal-3 concen-
trations in older subjects (> 45 years). This is in ac-
cordance with previous findings (11,19,20). In par-
ticular, Gaze et al. stratified the study population 
by age (≥ 50 years and < 50 years), and observed a 
consistent trend, with increasing Gal-3 concentra-
tions in parallel with ageing, thus finally conclud-
ing that two different URLs may be used in sub-
jects ≥ 50 years or in those < 50 years (35.1 ng/mL 
and 25.5 ng/mL, respectively) (11). Krintus et al. 
found that the URL of Gal-3 was only slightly high-
er in older (≥ 40 years) compared to younger sub-
jects (18.8 vs 17.9 ng/mL, respectively) (19). Mueller 
et al. also found a weak but still statistically signifi-
cant association between Gal-3 concentrations 
and age (20). 
To the best of our knowledge, our study is the first 
that allow defining reference values of Gal-3 in a 
highly reliable reference population, using strict 
criteria for including only healthy subjects and 
with a representative number of individuals in dif-
ferent age and sex categories. 
The discrepancies observed among our findings 
and data of previous studies may be justified by 
some important aspects. First, the selection of a 
“really” healthy population is essential for accu-
rately defining reference values of any clinically us-
able biomarker. However, how to precisely define 
a “healthy” reference population is currently de-
batable (23,24). Apple and Collinson recently de-
fined what should constitute a healthy reference 
population, by emphasizing that the selection 
should be based on history of medications and 
the presence of a known underlying disease, as 
well as by identifying the possible presence of oc-
cult organ dysfunction by measuring some surro-
gate biomarkers (25). The vast majority of the stud-
ies aimed to define the reference values of Gal-3 
lacks an accurate description of the study popula-
tion, but rather simply indicate that the subjects 
were “healthy without known cardiac disease” (11-
13). Only two studies so far have accurately de-
scribed the reference “healthy” population, also 
clearly applying stringent exclusion criteria (19-20). 
However, both studies mainly included young in-
dividuals (≤ 45 years), whereas an appropriate 
number of older subjects was included in our in-
vestigation. This difference could hence explain 
the higher Gal-3 URL observed in our study popu-
lation. A strong association between Gal-3 and 
age has been earlier reported by de Boer et al. in a 
large sample of the general population (26).   
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The sample size is another well-established critical 
issue for accurately defining the reference values 
of biomarkers. The CLSI recommends a minimum 
of 120 individuals (17). This number is mandatory 
to use a nonparametric estimation method for cal-
culating the limits of a central 95% reference inter-
val with upper limit at 97.5th percentile. When 
stratifying the population according to possible 
determinants, each homogenous subclass should 
hence be represented by not less than 120 individ-
uals. Therefore, when age- and sex-related differ-
ences need to be considered, the minimum num-
ber of healthy individuals escalates in parallel. Ac-
cordingly, the considerable number of subjects in 
each of the different population clusters (stratified 
by age, sex and renal function) should be seen as a 
major strength of our study. A potential limitation 
is the inclusion of only Caucasian individuals, 
which may hamper data transferability to other 
ethnic groups. 
In conclusion, this is the first study aimed to define 
the URL of Gal-3 performed on a highly selected 
healthy population, stratified according to age and 
sex. Our findings clearly suggest that age may be 
an important determinant of Gal-3 plasma con-
centration, so that multiple diagnostic cut-offs 
should be preferably used according to the differ-
ent age classes. 
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